SHetA2 Therapy: A Promising Oral Treatment for HPV-Related Cervical Cancer

Context

A new oral therapy, SHetA2, has shown promising results in preventing Human Papillomavirus (HPV) infection from progressing to cervical cancer.

About SHetA2 Therapy

1. SHetA2 is a small molecule therapy comprising low-molecular-weight compounds that are readily absorbed by the body.
2. It is being developed to treat HPV-induced cervical dysplasia (abnormal precancerous changes in cervical cells) and cervical cancer.
3. Currently under evaluation as an oral capsule, the therapy is intended for individuals with HPV-induced precancerous cervical lesions.
4. SHetA2 targets three human proteins—mortalin, Heat Shock Cognate 70 (Hsc70), and Glucose-Regulated Protein 78 (Grp78)—that support the activity of the HPV E7 oncoprotein (a cancer-promoting viral protein). By disrupting the interaction between the E7 protein and a host cell protein, it enables the body’s natural defence mechanisms to eliminate the viral protein, thereby preventing further damage to healthy cells.
5. Human Papillomavirus (HPV) is the most common sexually transmitted infection (STI), with more than 100 identified types.
6. Most HPV infections resolve naturally without treatment. However, some low-risk types cause genital warts, while high-risk strains can lead to cervical and other cancers.
7. HPV spreads through skin-to-skin contact, mainly during vaginal, anal, and oral sexual contact. Around 80% of both men and women acquire HPV infection at some point in their lives.
8. Symptoms may include genital or anal warts and, in some cases, cancerous growths of the cervix, mouth, or throat.
9. Although there is no cure for HPV infection, HPV vaccination remains the most effective measure to prevent HPV-related cancers.

FAQs

Q1. Why is SHetA2 Therapy in the news?

Ans: SHetA2 has shown promising results in preventing HPV infection from progressing to cervical cancer, making it a potential targeted therapy for HPV-related cervical disease.

Q2. What is SHetA2 Therapy?

Ans: SHetA2 is a small molecule therapy being developed to treat HPV-induced cervical dysplasia and cervical cancer. It is currently being evaluated in oral capsule form.

Q3. How does SHetA2 Therapy work?

Ans: SHetA2 targets the human proteins mortalin, Hsc70, and Grp78, disrupting the interaction between the HPV E7 oncoprotein and a host protein. This enables the body to eliminate the viral protein and prevent cancer progression.

Q4. What is Human Papillomavirus (HPV)?

Ans: HPV is the most common sexually transmitted infection, with more than 100 identified types. While most infections resolve naturally, certain high-risk strains can cause cervical and other cancers.

Q5. How is HPV transmitted?

Ans: HPV is transmitted through skin-to-skin contact, primarily during vaginal, anal, and oral sexual contact.

Q6. Can HPV infection be cured?

Ans: There is no cure for HPV infection. However, HPV vaccination is the most effective way to prevent HPV-related cancers.

Q7. Who can benefit from SHetA2 Therapy?

Ans: SHetA2 is intended for individuals with HPV-induced precancerous cervical lesions, with the aim of preventing their progression to cervical cancer.